Effect of Omega-3 Fatty Acid on the Fatty Acid Content of the Erythrocyte Membrane and Proteinuria in Patients with Diabetic Nephropathy

Su Mi Lee, Seuk Hee Chung, Yongjin Park, Mi Kyoung Park, Young Ki Son, Seong Eun Kim, Won Suk An, Su Mi Lee, Seuk Hee Chung, Yongjin Park, Mi Kyoung Park, Young Ki Son, Seong Eun Kim, Won Suk An

Abstract

Diabetic nephropathy is the leading cause of end-stage renal disease and is associated with an increased risk of cardiovascular events. Dietary omega-3 fatty acid (FA) has cardioprotective effect and is associated with a slower deterioration of albumin excretion in patients with diabetic nephropathy. In this study, we evaluated the effect of omega-3 FA on proteinuria in diabetic nephropathy patients who are controlling blood pressure (BP) with angiotensin converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB). In addition, we identified changes in erythrocyte membrane FA contents. A total of 19 patients who were treated with ACEi or ARB for at least 6 months were treated for 12 weeks with omega-3 FA (Omacor, 3 g/day) or a control treatment (olive oil, 3 g/day). Proteinuria levels were unchanged after 12 weeks compared with baseline values in both groups. The erythrocyte membrane contents of omega-3 FA and eicosapentaenoic acid (EPA) were significantly increased, and oleic acid, arachidonic acid : EPA ratio, and omega-6 : omega-3 FA ratio were significantly decreased after 12 weeks compared with the baseline values in the omega-3 FA group. Although omega-3 FA did not appear to alter proteinuria, erythrocyte membrane FA contents, including oleic acid, were altered by omega-3 FA supplementation.

References

    1. de Boer I. H., Rue T. C., Hall Y. N., Heagerty P. J., Weiss N. S., Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. Journal of the American Medical Association. 2011;305(24):2532–2539. doi: 10.1001/jama.2011.861.
    1. Imai E., Ito S., Haneda M., Chan J. C. N., Makino H. Olmesartan reducing incidence of endstage renal disease in diabetic nephropathy trial (orient): Rationale and study design. Hypertension Research. 2006;29(9):703–709. doi: 10.1291/hypres.29.703.
    1. de Zeeuw D., Remuzzi G., Parving H.-H., et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney International. 2004;65(6):2309–2320. doi: 10.1111/j.1523-1755.2004.00653.x.
    1. Shimizu H., Ohtani K.-I., Tanaka Y., Sato N., Mori M., Shimomura Y. Long-term effect of eicosapentaenoic acid ethyl (EPA-E) on albuminuria of non-insulin dependent diabetic patients. Diabetes Research and Clinical Practice. 1995;28(1):35–40. doi: 10.1016/0168-8227(95)01056-J.
    1. Möllsten A. V., Dahlquist G. G., Stattin E.-L., Rudberg S. Higher intakes of fish protein are related to a lower risk of microalbuminuria in young swedish type 1 diabetic patients. Diabetes Care. 2001;24(5):805–810. doi: 10.2337/diacare.24.5.805.
    1. Garman J. H., Mulroney S., Manigrasso M., Flynn E., Marie C. Omega-3 fatty acid rich diet prevents diabetic renal disease. American Journal of Physiology—Renal Physiology. 2009;296(2):F306–F316. doi: 10.1152/ajprenal.90326.2008.
    1. Krentz A. J., Clough G., Byrne C. D. Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications. Diabetes, Obesity and Metabolism. 2007;9(6):781–791. doi: 10.1111/j.1463-1326.2007.00670.x.
    1. Gerstein H. C., Mann J. F. E., Yi Q., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. The Journal of the American Medical Association. 2001;286(4):421–426. doi: 10.1001/jama.286.4.421.
    1. Svensson M., Schmidt E. B., Jørgensen K. A., Christensen J. H. N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial. Clinical journal of the American Society of Nephrology. 2006;1(4):780–786. doi: 10.2215/CJN.00630206.
    1. Hu F. B., Bronner L., Willett W. C., et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. The Journal of the American Medical Association. 2002;287(14):1815–1821. doi: 10.1001/jama.287.14.1815.
    1. Lee S. M., An W. S. Cardioprotective effects of ω-3 PUFAs in chronic kidney disease. BioMed Research International. 2013;2013:8. doi: 10.1155/2013/712949.712949
    1. Burr M. L., Fehily A. M., Gilbert J. F., et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial (DART) The Lancet. 1989;2(8666):757–761.
    1. Marchioli R. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin e after myocardial infarction: results of the gissi-prevenzione trial. Gruppo italiano per lo studio della sopravvivenza nell'infarto miocardico. The Lancet. 1999;354(9177):447–455. doi: 10.1016/S0140-6736(99)07072-5.
    1. Rizos E. C., Ntzani E. E., Elisaf M. S. Omega-3 fatty acid supplementation and cardiovascular disease events—قeply. JAMA - Journal of the American Medical Association. 2013;309(1):p. 29. doi: 10.1001/jama.2012.116657.
    1. Christensen J. H., Aarup Skou H., Madsen T., Tørring I., Berg Schmidt E. Heart rate variability and n-3 polyunsaturated fatty acids in patients with diabetes mellitus. Journal of Internal Medicine. 2001;249(6):545–552. doi: 10.1046/j.1365-2796.2001.00841.x.
    1. Siguel E. N., Lerman R. H. Altered fatty acid metabolism in patients with angiographically documented coronary artery disease. Metabolism: Clinical and Experimental. 1994;43(8):982–993. doi: 10.1016/0026-0495(94)90178-3.
    1. Paganelli F., Maixent J. M., Duran M. J., Parhizgar R., Pieroni G., Sennoune S. Altered erythrocyte n-3 fatty acids in Mediterranean patients with coronary artery disease. International Journal of Cardiology. 2001;78(1):27–32. doi: 10.1016/S0167-5273(00)00442-3.
    1. Block R. C., Harris W. S., Reid K. J., Spertus J. A. Omega-6 and trans fatty acids in blood cell membranes: a risk factor for acute coronary syndromes? American Heart Journal. 2008;156(6):1117–1123. doi: 10.1016/j.ahj.2008.07.014.
    1. Gross J. L., de Azevedo M. J., Silveiro S. P., Canani L. H., Caramori M. L., Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164–176. doi: 10.2337/diacare.28.1.164.
    1. Oh J. S., Kim S. M., Sin Y. H., et al. Comparison of erythrocyte membrane fatty acid contents in renal transplant recipients and dialysis patients. Transplantation Proceedings. 2012;44(10):2932–2935. doi: 10.1016/j.transproceed.2012.04.041.
    1. Jo S., An W.-S., Park Y. Erythrocyte n-3 polyunsaturated fatty acids and the risk of type 2 diabetes in koreans: a case-control study. Annals of Nutrition and Metabolism. 2014;63(4):283–290. doi: 10.1159/000357018.
    1. An W. S., Lee S. M., Son Y. K., et al. Effect of omega-3 fatty acids on the modification of erythrocyte membrane fatty acid content including oleic acid in peritoneal dialysis patients. Prostaglandins Leukotrienes and Essential Fatty Acids. 2012;86(1-2):29–34. doi: 10.1016/j.plefa.2011.10.009.
    1. An W. S., Lee S. M., Son Y. K., et al. Omega-3 fatty acid supplementation increases 1,25-dihydroxyvitamin D and fetuin-A levels in dialysis patients. Nutrition Research. 2012;32(7):495–502. doi: 10.1016/j.nutres.2012.06.005.
    1. Namayandeh S. M., Kaseb F., Lesan S. Olive and sesame oil effect on lipid profile in hypercholesterolemic patients, which better? International Journal of Preventive Medicine. 2013;4(9):1059–1062.
    1. Trevisan M., Krogh V., Freudenheim J., et al. Consumption of olive oil, butter, and vegetable oils and coronary heart disease risk factors. The Journal of the American Medical Association. 1990;263(5):688–692. doi: 10.1001/jama.263.5.688.
    1. Navarro M. D., Periago J. L., Pita M. L., Hortelano P. The n-3 polyunsaturated fatty acid levels in rat tissue lipids increase in response to dietary olive oil relative to sunflower oil. Lipids. 1994;29(12):845–848. doi: 10.1007/BF02536252.
    1. Green C. D., Ozguden-Akkoc C. G., Wang Y., Jump D. B., Olson L. K. Role of fatty acid elongases in determination of de novo synthesized monounsaturated fatty acid species. Journal of Lipid Research. 2010;51(7):1871–1877. doi: 10.1194/jlr.M004747.
    1. Perkins B. A., Ficociello L. H., Ostrander B. E., et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. Journal of the American Society of Nephrology. 2007;18(4):1353–1361. doi: 10.1681/ASN.2006080872.
    1. Lewis E. J., Hunsicker L. G., Bain R. P., Rohde R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The New England Journal of Medicine. 1993;329(20):1456–1462. doi: 10.1056/NEJM199311113292004.
    1. Lewis E. J., Hunsicker L. G., Clarke W. R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. The New England Journal of Medicine. 2001;345(12):851–860. doi: 10.1056/NEJMoa011303.
    1. Nakao N., Yoshimura A., Morita H., Takada M., Kayano T., Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. The Lancet. 2003;361(9352):117–124. doi: 10.1016/S0140-6736(03)12229-5.
    1. Cortinovis M., Cattaneo D., Perico N., Remuzzi G. Investigational drugs for diabetic nephropathy. Expert Opinion on Investigational Drugs. 2008;17(10):1487–1500. doi: 10.1517/13543784.17.10.1487.
    1. Fioretto P., Caramori M. L., Mauer M. The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007. Diabetologia. 2008;51(8):1347–1355. doi: 10.1007/s00125-008-1051-7.
    1. Barcelli U. O., Miyata J., Ito Y., et al. Beneficial effects of polyunsaturated fatty acids in partially nephrectomized rats. Prostaglandins. 1986;32(2):211–219.
    1. An W. S., Kim H. J., Cho K.-H., Vaziri N. D. Omega-3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in the remnant kidney. American Journal of Physiology—Renal Physiology. 2009;297(4):F895–F903. doi: 10.1152/ajprenal.00217.2009.
    1. Lauretani F., Maggio M., Pizzarelli F., et al. Omega-3 and renal function in older adults. Current Pharmaceutical Design. 2009;15(36):4149–4156. doi: 10.2174/138161209789909719.
    1. Donadio J. V., Jr., Larson T. S., Bergstralh E. J., Grande J. P. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. Journal of the American Society of Nephrology. 2001;12(4):791–799.
    1. Lauretani F., Semba R. D., Bandinelli S., et al. Plasma polyunsaturated fatty acids and the decline of renal function. Clinical Chemistry. 2008;54(3):475–481. doi: 10.1373/clinchem.2007.095521.
    1. Esposito K., Marfella R., Ciotola M., et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. The Journal of the American Medical Association. 2004;292(12):1440–1446. doi: 10.1001/jama.292.12.1440.
    1. Perez-Jimenez F., de Cienfuegos G. A., Badimon L., et al. International conference on the healthy effect of virgin olive oil. European Journal of Clinical Investigation. 2005;35(7):421–424. doi: 10.1111/j.1365-2362.2005.01516.x.
    1. Friedberg C. E., Janssen M. J. F. M., Heine R. J., Grobbee D. E. Fish oil and glycemic control in diabetes. A meta-analysis. Diabetes Care. 1998;21(4):494–500. doi: 10.2337/diacare.21.4.494.
    1. Montori V. M., Farmer A., Wollan P. C., Dinneen S. F. Fish oil supplementation in type 2 diabetes: a quantitative systematic review. Diabetes Care. 2000;23(9):1407–1415. doi: 10.2337/diacare.23.9.1407.
    1. Nielsen S. E., Schjoedt K. J., Astrup A. S., et al. Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. Diabetic Medicine. 2010;27(10):1144–1150. doi: 10.1111/j.1464-5491.2010.03083.x.
    1. Bolignano D., Lacquaniti A., Coppolino G., et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clinical Journal of the American Society of Nephrology. 2009;4(2):337–344. doi: 10.2215/CJN.03530708.
    1. Harris R. C. COX-2 and the kidney. Journal of Cardiovascular Pharmacology. 2006;47(supplement 1):S37–S42. doi: 10.1097/00005344-200605001-00007.
    1. Câmara N. O. S., Martins J. O., Landgraf R. G., Jancar S. Emerging roles for eicosanoids in renal diseases. Current Opinion in Nephrology and Hypertension. 2009;18(1):21–27. doi: 10.1097/MNH.0b013e32831a9df7.
    1. McDaniel M. L., Kwon G., Hill J. R., Marshall C. A., Corbett J. A. Cytokines and nitric oxide in islet inflammation and diabetes. Proceedings of the Society for Experimental Biology and Medicine. 1996;211(1):24–32. doi: 10.3181/00379727-211-43950D.
    1. Persaud S. J., Muller D., Belin V. D., et al. The role of arachidonic acid and its metabolites in insulin secretion from human islets of langerhans. Diabetes. 2007;56(1):197–203. doi: 10.2337/db06-0490.
    1. Wei D., Li J., Shen M., et al. Cellular production of n-3 PUFAs and reduction of n-6 -to-n-3 ratios in the pancreatic β-cells and islets enhance insulin secretion and confer protection against cytokine-induced cell death. Diabetes. 2010;59(2):471–478. doi: 10.2337/db09-0284.
    1. Bellenger J., Bellenger S., Bataille A., et al. High pancreatic n-3 fatty acids prevent STZ-induced diabetes in fat-1 mice: inflammatory pathway inhibition. Diabetes. 2011;60(4):1090–1099. doi: 10.2337/db10-0901.
    1. Lovejoy J. C. The influence of dietary fat on insulin resistance. Current Diabetes Reports. 2002;2(5):435–440. doi: 10.1007/s11892-002-0098-y.
    1. Jafari T., Fallah A. A., Azadbakht L. Role of dietary n-3 polyunsaturated fatty acids in type 2 diabetes: a review of epidemiological and clinical studies. Maturitas. 2013;74(4):303–308. doi: 10.1016/j.maturitas.2013.01.008.
    1. Zheng J.-S., Huang T., Yang J., Fu Y.-Q., Li D. Marine n-3 polyunsaturated fatty acids are inversely associated with risk of type 2 diabetes in asians: a systematic review and meta-analysis. PLoS ONE. 2012;7(9) doi: 10.1371/journal.pone.0044525.e44525

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera